Encapsulation of new MPI tracer nanoparticles in the human red blood cells
Standard
Encapsulation of new MPI tracer nanoparticles in the human red blood cells. / Antonelli, A.; Szwargulski, P.; Scarpa, E. S.; Grüttner, C.; Guidi, L.; Ambrosi, G.; Knopp, T.; Magnani, M.
in: Int J Magn Part Imag, Jahrgang 6, Nr. 2, 2009001, 2020.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › Andere (Vorworte u.ä.) › Forschung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Encapsulation of new MPI tracer nanoparticles in the human red blood cells
AU - Antonelli, A.
AU - Szwargulski, P.
AU - Scarpa, E. S.
AU - Grüttner, C.
AU - Guidi, L.
AU - Ambrosi, G.
AU - Knopp, T.
AU - Magnani, M.
N1 - Publisher Copyright: © 2020 Antonelli et al.; licensee Infinite Science Publishing GmbH.
PY - 2020
Y1 - 2020
N2 - Although Magnetic Particle Imaging (MPI) is not yet in clinical use, it is highly promising for several medical ap-plications, and especially for applications in diagnostic vascular in vivo imaging and imaging-guided vascular interventions. Furthermore, in the last years, different superparamagnetic iron oxide (SPIO) based contrast agents have been developed and approved for niche clinical applications in Magnetic Resonance Imaging (MRI) as alterna-tive to Gadolinium-based contrast agents (GBCAs) due to the risk for patients suffering from kidney dysfunction or nephrogenic systemic fibrosis (NSF). Recently, the potential of RBCs loaded with different SPIO nanoparticles as blood-pool tracer agents with longer blood retention time for MRI and MPI has been investigated. Here, we report the first in vitro results with the highly efficient dextran-based MPI tracer particles perimag® and synomag®-D to study their eligibility to be encapsulated into human RBCs and the potential of these new SPIO-RBC constructs as tracer material for MPI.
AB - Although Magnetic Particle Imaging (MPI) is not yet in clinical use, it is highly promising for several medical ap-plications, and especially for applications in diagnostic vascular in vivo imaging and imaging-guided vascular interventions. Furthermore, in the last years, different superparamagnetic iron oxide (SPIO) based contrast agents have been developed and approved for niche clinical applications in Magnetic Resonance Imaging (MRI) as alterna-tive to Gadolinium-based contrast agents (GBCAs) due to the risk for patients suffering from kidney dysfunction or nephrogenic systemic fibrosis (NSF). Recently, the potential of RBCs loaded with different SPIO nanoparticles as blood-pool tracer agents with longer blood retention time for MRI and MPI has been investigated. Here, we report the first in vitro results with the highly efficient dextran-based MPI tracer particles perimag® and synomag®-D to study their eligibility to be encapsulated into human RBCs and the potential of these new SPIO-RBC constructs as tracer material for MPI.
U2 - 10.18416/IJMPI.2020.2009001
DO - 10.18416/IJMPI.2020.2009001
M3 - Other (editorial matter etc.)
AN - SCOPUS:85090279676
VL - 6
JO - Int J Magn Part Imag
JF - Int J Magn Part Imag
SN - 2365-9033
IS - 2
M1 - 2009001
ER -
